CMS advised all shareholders of AMW GmbH on sale to Ren Life Sciences and Juno Capital Partners

Hamburg/Munich – The shareholders of AMW GmbH, a leading specialty pharmaceutical company focusing on biodegradable systems for controlled drug delivery, have sold a majority stake in AMW GmbH to Ren Life Sciences and Juno Capital Partners. Ren Life Sciences, a specialist investment firm focused on European life sciences companies, and Juno Capital Partners, a global investor based in Toronto, acquired a majority stake from the previous shareholders. Two existing shareholders are retaining their stakes: SHS Capital, the first investor in AMW GmbH, and AMW Evolution, a special purpose vehicle established by the advisory board, management and employees. SHS Capital exited its investment in AMW GmbH through a prior fund and reinvested through a current fund. This marks the continuation of the long-standing partnership with the healthcare specialist. The parties did not disclose the details of the purchase price.

A CMS team led by private equity specialist Dr Jacob Siebert provided comprehensive advice on the transaction to the shareholders who sold their stakes and, together with co-lead Dr Andreas Lohbeck, advised on the buy-back and structuring of the future management participation.

Founded in 2008 and based in Warngau in the Munich area, AMW GmbH specialises in biodegradable implants for controlled drug delivery systems. The company covers the entire value chain, from (co-)development and manufacturing to international marketing. AMW GmbH has two approved products, goserelin and leuprorelin implants, which are distributed worldwide through local sales and licensing partnerships with international pharmaceutical companies. Following another record year in 2025, the company plans to further accelerate its international expansion with the new shareholders.

Press Contact 
presse@cms-hs.com